$803.1 M

AKRO Mkt cap, 28-Sept-2021
Akero Therapeutics Net income (Q1, 2021)-15.1 M
Akero Therapeutics EBIT (Q1, 2021)-15.1 M
Akero Therapeutics Cash, 31-Mar-2021188 M
Akero Therapeutics EV616.6 M
Get notified regarding key financial metrics and revenue changes at Akero TherapeuticsLearn more
Banner background

Akero Therapeutics Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

R&D expense

3.5m11.9m37.0m64.9m

General and administrative expense

1.1m1.9m8.6m15.2m

Operating expense total

4.6m13.8m45.7m80.2m

EBIT

(4.6m)(13.8m)(45.7m)(80.2m)

Interest income

1.9m947.0k

Income tax expense

24.0k

Net Income

(4.6m)(81.7m)(43.8m)(79.2m)

Quarterly

USDQ3, 2019Q1, 2020Q2, 2020Q1, 2021

R&D expense

13.9m8.8m13.0m10.6m

General and administrative expense

2.4m3.6m3.4m4.5m

Operating expense total

16.3m12.4m16.5m15.1m

EBIT

(16.3m)(12.4m)(16.5m)(15.1m)

Interest income

755.0k493.0k247.0k38.0k

Income tax expense

Net Income

(15.6m)(11.9m)(16.2m)(15.1m)

Akero Therapeutics Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

598.0k76.0m64.8m187.2m

Prepaid Expenses

40.0k1.2m1.6m3.0m

Current Assets

638.0k77.1m138.0m271.3m

PP&E

131.0k

Total Assets

658.0k77.2m138.1m273.3m

Accounts Payable

60.0k1.4m947.0k3.4m

Current Liabilities

222.0k2.3m9.4m13.1m

Long-term debt

1.5m

Total Debt

1.5m

Total Liabilities

9.4m14.6m

Common Stock

3.0k4.0k

Preferred Stock

5.0m124.7m

Additional Paid-in Capital

33.6m259.0m468.2m

Retained Earnings

(4.6m)(86.6m)(130.3m)(209.5m)

Total Equity

436.0k74.8m128.7m258.7m

Financial Leverage

1.5 x1 x1.1 x1.1 x

Quarterly

USDQ3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

147.8m47.2m63.2m188.0m

Prepaid Expenses

2.2m933.0k10.4m5.8m

Current Assets

150.1m126.2m113.2m255.8m

PP&E

120.0k

Total Assets

150.1m126.6m114.1m257.6m

Accounts Payable

93.0k1.5m2.5m4.6m

Current Liabilities

6.7m8.3m10.4m10.1m

Long-term debt

1.5m

Total Debt

1.5m

Total Liabilities

6.8m8.3m10.4m11.6m

Common Stock

3.0k3.0k3.0k4.0k

Additional Paid-in Capital

258.1m260.5m262.0m470.6m

Retained Earnings

(114.7m)(142.2m)(158.4m)(224.6m)

Total Equity

143.4m118.3m103.7m246.0m

Financial Leverage

1 x1.1 x1.1 x1 x

Akero Therapeutics Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(4.6m)(81.7m)(43.8m)(79.2m)

Depreciation and Amortization

17.0k

Accounts Payable

60.0k1.3m(426.0k)2.5m

Cash From Operating Activities

(4.4m)(4.6m)(35.6m)(70.8m)

Purchases of PP&E

(148.0k)

Cash From Investing Activities

(5.0m)(71.5m)(9.8m)

Cash From Financing Activities

5.0m85.0m96.0m203.1m

Net Change in Cash

618.0k75.4m(11.2m)122.5m

Quarterly

USDQ3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(28.1m)(11.9m)(28.1m)(15.1m)

Depreciation and Amortization

11.0k

Accounts Payable

(1.3m)588.0k1.6m1.2m

Cash From Operating Activities

(24.0m)(11.3m)(33.9m)(18.3m)

Cash From Investing Activities

(6.3m)32.2m19.0m

Cash From Financing Activities

95.9m164.0k264.0k24.0k

Net Change in Cash

71.9m(17.4m)(1.5m)678.0k

Akero Therapeutics Ratios

USDFY, 2017

Financial Leverage

1.5 x